Search results for "QUINAZOLINE"

showing 10 items of 67 documents

Synthesis of the new ring system 6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline

2009

Abstract A convenient synthesis of the pyrrolo[3,4- h ]quinazoline ring system is reported. Our synthetic approach consisted of the annelation of a pyrimidine ring to an isoindole moiety using tetrahydroisoindole-4-ones as building blocks. The antiproliferative activity of the new compounds was investigated and one of them showed antitumor activity against all the 59 tested cell lines at micromolar concentrations (1.46–18.4 μM).

Antitumor activityAnnulationPyrimidineStereochemistryOrganic ChemistryIsoindole building blocksAntiproliferative activityRing (chemistry)Biochemistry4-h ]quinazolinesSettore CHIM/08 - Chimica FarmaceuticaIsoindole building blockchemistry.chemical_compoundchemistryPyrimidine annelationDrug DiscoveryPyrrolo[3; 4-h ]quinazolines; Antiproliferative activity; Isoindole building blocks; Pyrimidine annelationQuinazolineMoietyPyrrolo[3Pyrrolo[34-h ]quinazolineIsoindole
researchProduct

ChemInform Abstract: Synthesis of the New Ring System 6,8-Dihydro-5H-pyrrolo[3,4-h]quinazoline.

2009

Abstract A convenient synthesis of the pyrrolo[3,4- h ]quinazoline ring system is reported. Our synthetic approach consisted of the annelation of a pyrimidine ring to an isoindole moiety using tetrahydroisoindole-4-ones as building blocks. The antiproliferative activity of the new compounds was investigated and one of them showed antitumor activity against all the 59 tested cell lines at micromolar concentrations (1.46–18.4 μM).

Antitumor activitychemistry.chemical_compoundAnnulationchemistryPyrimidineStereochemistryQuinazolineMoietyGeneral MedicineIsoindoleRing (chemistry)Combinatorial chemistryChemInform
researchProduct

Crystal structure of 5-(5,6-dihydrobenzo[4,5]imidazo[1,2-c]quinazolin-6-yl)-2-methoxyphenol

2015

In the molecule of the title compound, C21H17N3O2, the 5,6-dihydrobenzimidazo[1,2-c]quinazoline moiety is disordered over two orientations about a pseudo-mirror plane, with a refined occupancy ratio of 0.863 (2):0.137 (2). The dihedral angles formed by the benzimidazole ring system and the benzene ring of the quinazoline group are 14.28 (5) and 4.7 (3)° for the major and minor disorder components, respectively. An intramolecular O—H...O hydrogen bond is present. In the crystal, molecules are linked by O—H...N hydrogen bonds, forming chains running parallel to [10-1].

Benzimidazolecrystal structurecyclizationCrystallographyHydrogen bondGeneral ChemistryCrystal structureDihedral angleCondensed Matter PhysicsRing (chemistry)BioinformaticsMedicinal chemistryData Reportschemistry.chemical_compoundchemistryQD901-999QuinazolineMoietyGeneral Materials Scienceimidazole derivativeBenzeneActa Crystallographica Section E: Crystallographic Communications
researchProduct

Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine

2012

Neutrophil gelatinase-associated lipocalin (NGAL, a.k.a Lnc2) is a member of the lipocalin family and has diverse roles. NGAL can stabilize matrix metalloproteinase-9 from autodegradation. NGAL is considered as a siderocalin that is important in the transport of iron. NGAL expression has also been associated with certain neoplasias and is implicated in the metastasis of breast cancer. In a previous study, we examined whether ectopic NGAL expression would alter the sensitivity of breast epithelial, breast and colorectal cancer cells to the effects of the chemotherapeutic drug doxorubicin. While abundant NGAL expression was detected in all the cells infected with a retrovirus encoding NGAL, t…

BenzylaminesBerberinemedicine.medical_treatmentDrug ResistanceGene ExpressionBCL-2; Berberine; Breast cancer; Calmodulin kinase; Colorectal cancer; EGFR; Inhibitor sensitivity; Lcn2; Lipocalins; NGAL; Rapamycin; Siderocalins; Targeted therapyPiperazinesMetastasisTargeted therapyNitrophenolsTargeted therapyBreast cancerAntibioticsNGALSulfonamidesAntibiotics AntineoplasticTumorSiderocalinsTyrphostinsAntineoplasticLipocalinsBiphenyl compoundErbB ReceptorsProto-Oncogene Proteins c-bcl-2MCF-7 CellsFemalelipocalinHT29 Cellsmedicine.drugbcl-2; breast cancer; lipocalins; targeted therapy; berberine; lcn2; colorectal cancer; rapamycin; inhibitor sensitivity; siderocalins; egfr; ngal; calmodulin kinaseCalmodulin kinasesiderocalinEGFRBCL-2Breast NeoplasmsSiderocalinBiologyNGAL Lcn2 lipocalins siderocalins targeted therapy inhibitor sensitivity EGFR rapamycin berberine BCL-2 calmodulin kinase breast cancer colorectal cancerCell LineHT29 CellsLcn2Lipocalin-2ReportCell Line TumorProto-Oncogene ProteinsmedicineHumansDoxorubicinRapamycinMolecular BiologyProtein Kinase InhibitorsSirolimusBiphenyl CompoundsCell Biologymedicine.diseaseColorectal cancerCell cultureDoxorubicinDrug Resistance NeoplasmCancer cellCalcium-Calmodulin-Dependent Protein KinasesCancer researchQuinazolinesNeoplasmInhibitor sensitivityDevelopmental BiologyAcute-Phase Proteins
researchProduct

β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations

2014

Abstract The discovery of somatic mutations in EGFR and development of EGFR tyrosine kinase inhibitors (TKI) have revolutionized treatment for lung cancer. However, resistance to TKIs emerges in almost all patients and currently no effective treatment is available. Here, we show that β-catenin is essential for development of EGFR-mutated lung cancers. β-Catenin was upregulated and activated in EGFR-mutated cells. Mutant EGFR preferentially bound to and tyrosine phosphorylated β-catenin, leading to an increase in β-catenin–mediated transactivation, particularly in cells harboring the gefitinib/erlotinib-resistant gatekeeper EGFR-T790M mutation. Pharmacologic inhibition of β-catenin suppresse…

Cancer ResearchLung NeoplasmsCarcinogenesisAfatinibMutation MissenseAntineoplastic AgentsMice TransgenicAfatinibmedicine.disease_causeArticleTransactivationGefitinibCarcinoma Non-Small-Cell LungCell Line TumormedicineAnimalsHumansEpidermal growth factor receptorLung cancerbeta CateninMutationbiologyProtein Stabilitymedicine.diseaseXenograft Model Antitumor AssaysTumor BurdenUp-Regulationrespiratory tract diseasesErbB ReceptorsGene Expression Regulation NeoplasticHEK293 CellsOncologyDoxycyclineCateninImmunologyQuinazolinesCancer researchbiology.proteinCarcinogenesismedicine.drugCancer Research
researchProduct

Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment r…

2012

Abstract Patients with lung cancer with activating mutations in the EGF receptor (EGFR) kinase, who are treated long-term with tyrosine kinase inhibitors (TKI), often develop secondary mutations in EGFR associated with resistance. Mice engineered to develop lung adenocarcinomas driven by the human EGFR T790M resistance mutation are similarly resistant to the EGFR TKI erlotinib. By tumor volume endpoint analysis, these mouse tumors respond to BIBW 2992 (an irreversible EGFR/HER2 TKI) and rapamycin combination therapy. To correlate EGFR-driven changes in the lung with response to drug treatment, we conducted an integrative analysis of global transcriptome and metabolite profiling compared wit…

Cancer ResearchLung NeoplasmsCombination therapyAfatinibGene ExpressionAdenocarcinoma of LungCell Growth ProcessesAdenocarcinomaAfatinibArticleErlotinib HydrochlorideMiceAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsEpidermal growth factor receptorLung cancerErlotinib HydrochlorideProtein Kinase InhibitorsSirolimusbiologymedicine.diseaserespiratory tract diseasesErbB ReceptorsOncologyTumor progressionDrug Resistance NeoplasmCancer researchbiology.proteinDisease ProgressionQuinazolinesErlotinibTyrosine kinasemedicine.drugTranscription FactorsCancer research
researchProduct

Analysis of Antiproliferative and Chemosensitizing Effects of Sunitinib on Human Esophagogastric Cancer Cells: Synergistic Interaction With Vandetani…

2009

The receptor tyrosine kinases (RTKs), epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 1-3 (VEGFR1-3), are frequently expressed in gastric cancer and are putative therapeutic targets in this disease. We have investigated the anti-proliferative and chemosensitizing properties of the multitargeted small-molecule RTK inhibitors sunitinib and vandetanib in a panel of 4 human gastric and esophageal cancer cell lines. In the 1st instance, the expression of potential targets of these small-molecule inhibitors was examined by reverse transcriptase-polymerase chain reaction, western blotting, and flow cytometry. EGFR mRNA and protein was detected in all cases, …

Cancer ResearchUmbilical VeinsIndolesEsophageal NeoplasmsApoptosisVandetanibTyrosine-kinase inhibitorReceptor tyrosine kinasechemistry.chemical_compoundPiperidinesSunitinibMedicineDrug InteractionsEpidermal growth factor receptorPhosphorylationCells CulturedbiologySunitinibReverse Transcriptase Polymerase Chain ReactionDrug SynergismFlow CytometryErbB ReceptorsOncologyPhosphorylationDrug Therapy Combinationmedicine.drugSignal Transductionmedicine.medical_specialtymedicine.drug_classBlotting WesternAntineoplastic AgentsStomach NeoplasmsInternal medicineHumansPyrrolesPropidium iodideRNA MessengerProtein Kinase InhibitorsCell ProliferationVascular Endothelial Growth Factor Receptor-1business.industryCancermedicine.diseaseVascular Endothelial Growth Factor Receptor-3Vascular Endothelial Growth Factor Receptor-2EndocrinologychemistryCancer researchbiology.proteinQuinazolinesEndothelium VascularbusinessProto-Oncogene Proteins c-akt
researchProduct

Parthenolide induces superoxide anion production by stimulating EGF receptor in MDA-MB-231 breast cancer cells

2013

The sesquiterpene lactone parthenolide (PN) has recently attracted considerable attention because of its anti-microbial, anti-inflammatory and anticancer effects. However, the mechanism of its cytotoxic action on tumor cells remains scarcely defined. We recently provided evidence that the effect exerted by PN in MDA-MB-231 breast cancer cells was mediated by the production of reactive oxygen species (ROS). The present study shows that PN promoted the phosphorylation of EGF receptor (phospho-EGFR) at Tyr1173, an event which was observed already at 1  h of incubation with 25  µM PN and reached a peak at 8-16  h. This effect seemed to be a consequence of ROS production, because N-acetylcystein…

Cancer Researchparthenolide epidermal growth factor receptor NADPH oxidase breast cancer cellsBreast NeoplasmsAntioxidantschemistry.chemical_compoundSuperoxidesCell Line TumorSettore BIO/10 - BiochimicaHumansParthenolideEnzyme InhibitorsPhosphorylationchemistry.chemical_classificationReactive oxygen speciesNADPH oxidasebiologySuperoxideKinaseAnti-Inflammatory Agents Non-SteroidalNF-kappa BAcetophenonesNADPH OxidasesTyrphostinsMolecular biologyAcetylcysteineErbB ReceptorsOncologychemistryApoptosisApocyninQuinazolinesbiology.proteinPhosphorylationFemaleProtein Tyrosine PhosphatasesSesquiterpenesInternational Journal of Oncology
researchProduct

Theoretical study on hydration of symmetrically different diazanaphthalenes

2005

Abstract Quinazoline (symmetrical) and quinoxaline (unsymmetrical), diazanaphthalenes involved in certain biological reactions, have been studied computational with the purpose of comparing their protonation and covalent hydration mechanisms. Geometry optimizations of neutral, mono and diprotonated cations and hydrated products have been carried out at three levels of theory. Geometry optimizations were performed at HF, DFT/B3LYP levels of theory using 6-311G* basis set and single point energies were calculated at the MP2 level of theory using the same basis set. In agreement with experimental results, calculations predict a two steps mechanism resulting in a hydrated cation in which the OH…

ChemistryDiazanaphthaleneProtonationCondensed Matter PhysicsEnergy minimizationBiochemistrychemistry.chemical_compoundQuinoxalineCovalent bondComputational chemistryQuinazolineMoleculePhysical and Theoretical ChemistryBasis setJournal of Molecular Structure: THEOCHEM
researchProduct

Mass spectrometry of 3,4-dihydroquinazol-4-ones of pharmaceutical interest. Part 2: Common structure of the C8H4N2R+ ions from 3-isoxazolyl-3-pyrazol…

1988

ChemistryOrganic ChemistryAnalytical chemistryQuinazolinesOrganic chemistryMass spectrometrySpectroscopyMass SpectrometryAnalytical ChemistryIonRapid communications in mass spectrometry : RCM
researchProduct